Jaime Hooley
Medical · Marshalltown, IANPI 1053668475
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,196 and has fallen 98.7% since, to $16 in 2024.
Across 135 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$426
- AstraZeneca$362
- AbbVie$300
- Lilly USA, LLC$240
- Novo Nordisk$223
- GSK$154
- plus $539 from 11 others
What the payments were for
- Food & beverage$2,245100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 28 | $426 |
| AstraZeneca | 16 | $362 |
| AbbVie | 19 | $300 |
| Lilly USA, LLC | 14 | $240 |
| Novo Nordisk | 13 | $223 |
| GSK | 11 | $154 |
| Johnson & Johnson | 6 | $91 |
| Astellas Pharma US Inc | 5 | $78 |
| Esperion Therapeutics, Inc. | 4 | $63 |
| Kowa Pharmaceuticals America, Inc. | 4 | $63 |
| Merck | 4 | $52 |
| Pfizer | 3 | $51 |
| Bayer | 2 | $50 |
| Novartis | 3 | $39 |
| Amarin Pharma, Inc. | 1 | $21 |
| Abbott | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,245 in reported general payments places this provider in the 85th percentile of 141 medical providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 114 | $138,886 |
| JardianceEmpagliflozin | 98 | $109,337 |
| FarxigaDapagliflozin Propanediol | 108 | $105,043 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $71,229 |
| EliquisApixaban | 64 | $67,912 |
| MounjaroTirzepatide | 49 | $57,173 |
| XareltoRivaroxaban | 48 | $45,600 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $26,635 |
| TrulicityDulaglutide | 19 | $26,534 |
| MyrbetriqMirabegron | 35 | $21,878 |
| RybelsusSemaglutide | 19 | $20,850 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $19,741 |
| JanuviaSitagliptin Phosphate | 15 | $16,210 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 21 | $10,816 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $5,866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $223 | $159,736133 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat | $426 | $125,423130 claims |
| AstraZenecaFarxiga, Symbicort | $362 | $110,909125 claims |
| Lilly USA, LLCMounjaro, Trulicity | $240 | $83,70768 claims |
| GSKTrelegy Ellipta | $154 | $71,22973 claims |
| PfizerEliquis | $51 | $67,91264 claims |
| Johnson & JohnsonXarelto | $91 | $45,60048 claims |
| Astellas Pharma US IncMyrbetriq | $78 | $21,87835 claims |
| MerckJanuvia | $52 | $16,21015 claims |
| AbbVieLumigan | $300 | $3,82414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 141 medical providers in Iowa.
Other medical in Marshalltown
- Patricia ArasonWest Des Moines$119K
- Maria SonnackIowa City$100K
- Kristin BabbAtlantic$16K
- Laura QuinnetteCouncil Bluffs$14K
- Laurie HughellUrbandale$9K
- Elizabeth McCullochWest Des Moines$6K
- Jordan GreinerPella$6K
- Samantha SmithBrooklyn$5K
- Emily EricksonDes Moines$5K
- Jennifer VandivierWest Des Moines$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.